Matthew C Kapusta sold $9.4M of QURE
CEO, Managing Director at uniQure N.V.. 226,316 shares at an average of $41.46, traded Sep 24, 2025, filed Sep 26, 2025.
Score components
- +25RoleCEO
- +25Trade size$9.4M at market
- +10Share of holdings soldSold 26% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000904454-25-000457, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 24, 2025 | MOption exercise Ordinary Shares10b5-1 | +51,316 | $7.53 | $386k | 702,770 | Sep 26, 2025 |
| Sep 24, 2025 | MOption exercise Ordinary Shares10b5-1 | +175,000 | $6.22 | $1.1M | 877,770 | Sep 26, 2025 |
| Sep 24, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -51,316 | $39.59 | $2.0M | 826,454 | Sep 26, 2025 |
| Sep 24, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $40.04 | $2.4M | 766,454 | Sep 26, 2025 |
| Sep 24, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -49,978 | $40.68 | $2.0M | 716,476 | Sep 26, 2025 |
| Sep 24, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -5,022 | $41.69 | $209k | 711,454 | Sep 26, 2025 |
| Sep 24, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $45.10 | $2.7M | 651,454 | Sep 26, 2025 |
| Sep 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -51,316 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Sep 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -175,000 | $0.00 | $0 | 0 | Sep 26, 2025 |
Related signals
Other insiders at uniQure N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | QUREsell uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $7,320 808 shares | -0% | |
| 15Weak | QUREsell uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $17k 1,660 shares | -1% | |
| 21Weak | uniQure N.V. | Robert Gut director | $857k 31,434 shares | -44% | |
| 33Weak | uniQure N.V. | Jack Kaye director | $1.2M 38,810 shares | -128% | |
| 19Weak | uniQure N.V. | Christian Klemt Chief Financial Officer | $945k 18,000 shares | -8% | |
| 30Weak | uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $20k 1,466 shares | -1% | |
| 35Weak | uniQure N.V. | Madhavan Balachandran director | $31k 2,112 shares | -5% | |
| 37Weak | uniQure N.V. | Robert Gut director | $48k 3,336 shares | -6% | |
| 35Weak | uniQure N.V. | Rachelle Suzanne Jacques director | $31k 2,112 shares | -7% | |
| 35Weak | uniQure N.V. | Jack Kaye director | $31k 2,112 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.